<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619512</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01978-45</org_study_id>
    <secondary_id>PSS2017/CGPSR-BROSÉUS/VS</secondary_id>
    <nct_id>NCT03619512</nct_id>
  </id_info>
  <brief_title>Genomic and Proteomic Study of Richter Syndrome (CGPSR)</brief_title>
  <acronym>CGPSR</acronym>
  <official_title>Genomic and Proteomic Study of Richter Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organization (FILO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic
      Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive
      Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to
      chemorefractoriness.

      This study aims at understanding the biological determinants of chemotherapy resistance in
      Richter Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the help of the French National Research Group on CLL (FILO / French Innovative Leukemia
      Organization), the investigators are currently gathering fresh frozen cell pellets at CLL
      stage, and lymph node biopsies at Richter stage. The investigators also gathered lymph node
      biopsies from DLBCL, as a reference group.

      The investigators will perform genomic and proteomic comparative studies between CLL and
      Richter, as well as between Richter and primitive DLBCL, to understand the biological
      determinants of clonal evolution and chemorefractoriness of Richter Syndrom.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">September 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Whole exome sequencing data using next generation sequencing method</measure>
    <time_frame>3 years</time_frame>
    <description>Comparison between the DNA sequences from Richter syndrome samples and DNA sequences from primitive DLBCL samples to identify a set of mutations that are specific to Richter syndrome.
For each position, the result is &quot;mutated&quot; or &quot;unmutated&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RNA sequencing data using next generation sequencing method</measure>
    <time_frame>3 years</time_frame>
    <description>Measurment of gene expression for all genes. Comparison of these expression levels between Richter samples, primitive DLBCL samples and normal lymph nodes to identifiy a set of genes which expression levels are different in Richter samples compared primitive DLBCL and normal lymph nodes.
Gene expression is a quatitative value. This set of genes forms a specific &quot;transcriptomic signature&quot; of Richter syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteomic analysis using mass spectrometry</measure>
    <time_frame>3 years</time_frame>
    <description>Mass spectrometry allows identification and measurment of the expression level of the 5,000 most expressed proteins in a sample. The investigators want to compare the protein expression levels between Richter samples, primitive DLBCL samples and normal lymph nodes to identifiy a set of proteins that are highly expressed in Richter samples (but not in primitive DLBCL or normal lymph nodes). This set of proteins forms a specific &quot;proteomic signature&quot; of Richter.
Protein expression is a quatitative value expressed as an absolute number of copies in a cell.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Richter Syndrome</condition>
  <arm_group>
    <arm_group_label>Richter Syndrom at diagnosis</arm_group_label>
    <description>patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primitive Diffuse Large B-Cell Lymphoma</arm_group_label>
    <description>patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other secundary Diffuse Large B-Cell Lymphoma</arm_group_label>
    <description>patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group with no tumor involvment of lymph nodes</arm_group_label>
    <description>patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole exome sequencing.</intervention_name>
    <description>Retrospective biological exploration of the samples, including tumoral DNA exploration.</description>
    <arm_group_label>Control group with no tumor involvment of lymph nodes</arm_group_label>
    <arm_group_label>Other secundary Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Primitive Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Richter Syndrom at diagnosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA sequencing</intervention_name>
    <description>Characterization of tumor transcriptomic profile.</description>
    <arm_group_label>Control group with no tumor involvment of lymph nodes</arm_group_label>
    <arm_group_label>Other secundary Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Primitive Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Richter Syndrom at diagnosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mass spectrometry</intervention_name>
    <description>Characterization of tumor proteomic profiles.</description>
    <arm_group_label>Control group with no tumor involvment of lymph nodes</arm_group_label>
    <arm_group_label>Other secundary Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Primitive Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Richter Syndrom at diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Diagnosis of Diffuse Large B-Cell Lymphoma arising in the context of a Chronic
             Lymphocytic Leukemia (group 1).

          -  Diagnosis of Diffuse Large B-Cell Lymphoma de novo (group 2).

          -  Diagnosis of Diffuse Large B-Cell Lymphoma arising in a context of small cells
             lymphoma, excluding CLL (group 3).

          -  Patients who benefited from a diagnostic lymph node biopsy that did not reveal any
             tumor involvment (primitive or metastatic) (group 4).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a Diffuse Large B-Cell Lymphoma arising in the context of a Chronic
             Lymphocytic Leukemia (group 1) or diagnosis of a primitive Diffuse Large B-Cell
             Lymphoma (group 2), or diagnosis of a Diffuse Large B-Cell Lymphoma arising in a
             context of small cells lymphoma, excluding CLL (group 3), or benefit from a diagnostic
             lymph node biopsy that did not reveal any tumor involvment (primitive or metastatic)
             (group 4).

          -  Patients must benefit from a lymph node biopsy at diagnosis.

          -  Patients must be followed by a FILO (French Innovative Leukemia Organization) member

          -  Histology of Diffuse Large B-Cell Lymphoma or Hodgkin histology.

          -  Suitable clinical data available.

          -  Samples must meet the following requirement :RIN (RNA Integrity Number) &gt; 5 et DIN
             (DNA Integrity Number) &gt; 6.5.

        Exclusion Criteria:

        • Samples that do not meet the inclusion criteria (insufficient clinical data, analysis
        impossible due to insufficient sample quality).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Broseus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Feugier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Broseus, MD, PhD</last_name>
    <phone>+ 33 (0)3 83 15 49 14</phone>
    <email>j.broseus@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Saunier</last_name>
    <phone>+ 33 (0)3 83 15 54 58</phone>
    <email>v.saunier@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique SAUNIER</last_name>
      <phone>+33 (0)3 83 15 54 58</phone>
      <email>v.saunier@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Broséus, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Feugier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rossi D, Spina V, Forconi F, Capello D, Fangazio M, Rasi S, Martini M, Gattei V, Ramponi A, Larocca LM, Bertoni F, Gaidano G. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. Int J Cancer. 2012 Jun 15;130(12):3006-10. doi: 10.1002/ijc.26322. Epub 2011 Aug 25.</citation>
    <PMID>21796624</PMID>
  </reference>
  <reference>
    <citation>Ferreira PG, Jares P, Rico D, Gómez-López G, Martínez-Trillos A, Villamor N, Ecker S, González-Pérez A, Knowles DG, Monlong J, Johnson R, Quesada V, Djebali S, Papasaikas P, López-Guerra M, Colomer D, Royo C, Cazorla M, Pinyol M, Clot G, Aymerich M, Rozman M, Kulis M, Tamborero D, Gouin A, Blanc J, Gut M, Gut I, Puente XS, Pisano DG, Martin-Subero JI, López-Bigas N, López-Guillermo A, Valencia A, López-Otín C, Campo E, Guigó R. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 2014 Feb;24(2):212-26. doi: 10.1101/gr.152132.112. Epub 2013 Nov 21.</citation>
    <PMID>24265505</PMID>
  </reference>
  <results_reference>
    <citation>Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, De Paoli L, Cresta S, Rasi S, Spina V, Franceschetti S, Lunghi M, Vendramin C, Bomben R, Ramponi A, Monga G, Conconi A, Magnani C, Gattei V, Gaidano G. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008 Jun;142(2):202-15. doi: 10.1111/j.1365-2141.2008.07166.x. Epub 2008 May 19.</citation>
    <PMID>18492108</PMID>
  </results_reference>
  <results_reference>
    <citation>Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013 Sep;162(6):774-82. doi: 10.1111/bjh.12458. Epub 2013 Jul 11.</citation>
    <PMID>23841899</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, Arcaini L, Lucioni M, Rocque GB, Xu-Monette ZY, Visco C, Chang J, Chigrinova E, Forconi F, Marasca R, Besson C, Papadaki T, Paulli M, Larocca LM, Pileri SA, Gattei V, Bertoni F, Foà R, Young KH, Gaidano G. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011 Mar 24;117(12):3391-401. doi: 10.1182/blood-2010-09-302174. Epub 2011 Jan 25.</citation>
    <PMID>21266718</PMID>
  </results_reference>
  <results_reference>
    <citation>Fangazio M, De Paoli L, Rossi D, Gaidano G. Predictive markers and driving factors behind Richter syndrome development. Expert Rev Anticancer Ther. 2011 Mar;11(3):433-42. doi: 10.1586/era.10.237. Review.</citation>
    <PMID>21417856</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R, Cresta S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R, Larocca LM, Foà R, Gaidano G. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012 Aug;158(3):426-9. doi: 10.1111/j.1365-2141.2012.09155.x. Epub 2012 May 10.</citation>
    <PMID>22571487</PMID>
  </results_reference>
  <results_reference>
    <citation>Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscier D, Bertoni F, Mullighan CG, Foá R, Pasqualucci L, Rabadan R, Dalla-Favera R, Gaidano G. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011 Jul 4;208(7):1389-401. doi: 10.1084/jem.20110921. Epub 2011 Jun 13.</citation>
    <PMID>21670202</PMID>
  </results_reference>
  <results_reference>
    <citation>Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013 Oct 10;122(15):2673-82. doi: 10.1182/blood-2013-03-489518. Epub 2013 Sep 4.</citation>
    <PMID>24004666</PMID>
  </results_reference>
  <results_reference>
    <citation>Scandurra M, Rossi D, Deambrogi C, Rancoita PM, Chigrinova E, Mian M, Cerri M, Rasi S, Sozzi E, Forconi F, Ponzoni M, Moreno SM, Piris MA, Inghirami G, Zucca E, Gattei V, Rinaldi A, Kwee I, Gaidano G, Bertoni F. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol. 2010 Jun;28(2):62-7. doi: 10.1002/hon.932.</citation>
    <PMID>20014148</PMID>
  </results_reference>
  <results_reference>
    <citation>Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, Pasqualucci L, Rabadan R, Dalla-Favera R. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013 Oct 21;210(11):2273-88. doi: 10.1084/jem.20131448. Epub 2013 Oct 14.</citation>
    <PMID>24127483</PMID>
  </results_reference>
  <results_reference>
    <citation>Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503-11.</citation>
    <PMID>10676951</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Richter Syndrome</keyword>
  <keyword>Genomics</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Chemotherapy resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

